Publications
Chosen filters:
Chosen filters:
Predicting disease-causing variant combinations Hasselt University Vrije Universiteit Brussel KU Leuven
Notwithstanding important advances in the context of single-variant pathogenicity identification, novel breakthroughs in discerning the origins of many rare diseases require methods able to identify more complex genetic models. We present here the Variant Combinations Pathogenicity Predictor (VarCoPP), a machine-learning approach that identifies pathogenic variant combinations in gene pairs (called digenic or bilocus variant combinations). We ...
Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy Ghent University University of Antwerp
Combinations of techniques that effectively change health behavior: Evidence from meta-CART analysis KU Leuven
OBJECTIVE: Many health-promoting interventions combine multiple behavior change techniques (BCTs) to maximize effectiveness. Although, in theory, BCTs can amplify each other, the available meta-analyses have not been able to identify specific combinations of techniques that provide synergistic effects. This study overcomes some of the shortcomings in the current methodology by applying classification and regression trees (CART) to meta-analytic ...
Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV type 1, HIV type 2, and selected carbohydrate-binding agent-resistant HIV type 1 strains KU Leuven
Abstract Carbohydrate-binding agents (CBAs) are potential HIV microbicidal agents with a high genetic barrier to resistance. We wanted to evaluate whether two mannose-specific CBAs, recognizing multiple and often distinct glycan structures on the HIV envelope gp120, can interact synergistically against HIV-1, HIV-2, and HIV-1 strains that were selected for resistance against particular CBAs [i.e., 2G12 mAb and microvirin (MVN)]. Paired CBA/CBA ...
Intratumoral gene transfer of immunomodulatory antibody combinations: a preclinical proof-of-concept study KU Leuven
Immune checkpoint inhibitors have emerged as a new promising treatment modality for cancer, as these monoclonal antibodies (mAbs) have been shown to enable durable responses in patients with various advanced and metastatic tumors. Still, a large proportion of cancer patients are refractory to this type of immunotherapy, which has led to a surging interest in combination treatments to improve response rates. These combination treatments, however, ...
Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment KU Leuven
Background-Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown.